Partner With Us · U.S. Market Access
Bring Your Biologic to the United States
The U.S. is the world's largest and most demanding biologics market. BioFutureRx partners with biologics companies outside the U.S. to navigate the regulatory pathway, structure the right deal, secure supply, and reach patients — drawing on an affiliated network with decades of U.S. and Canadian in-licensing experience.
The Opportunity
The largest biologics market — and the hardest to enter alone
For a biologic developed outside the United States, the U.S. represents the single largest commercial prize — and a maze of FDA requirements, payer dynamics, and channel complexity. A strong product is necessary but not sufficient; entering well takes a partner who has done it before.
That is the role BioFutureRx plays. We act as your U.S. counterpart — owning the regulatory, commercial, and supply work it takes to turn an ex-U.S. biologic into a U.S. product.
#1
The United States is the world's largest market for biologic medicines — and a top priority for any developer with global ambitions.
How We Help
A full-service U.S. partner for ex-U.S. biologics
From first assessment through launch, we bring the capabilities a cross-border biologics partnership demands.
U.S. Market-Entry Strategy
We assess where your biologic fits in the U.S. landscape — competitive positioning, pricing, and the commercial route most likely to win — and build the entry plan around it.
Regulatory Pathway
Guidance through FDA strategy for biologics and biosimilars — BLA and the 351(k) biosimilar pathway, interchangeability, and the data and CMC requirements that gate approval.
In-Licensing & Deal Structuring
We structure the license, distribution, or partnership agreement that aligns incentives — drawing directly on our group's track record structuring U.S. and Canadian in-licensing deals.
Manufacturing & Supply
Through long-standing Asia-Pacific manufacturing relationships, we help secure the CMC, supply, and quality footprint a U.S. launch depends on.
Market Access & Reimbursement
Payer strategy, coding and reimbursement, and channel access — the commercial groundwork that determines whether an approved biologic actually reaches patients.
An Affiliated Network
BioFutureRx works alongside sister companies in pharmaceutical in-licensing and capital, extending the reach, relationships, and financing a cross-border launch requires.
From Anywhere to the U.S.
We connect biologics from around the world to the U.S. market
Wherever your program originates, we become your single U.S. counterpart — regulatory, commercial, and supply — turning global innovation into American market access.
Decades of cross-border licensing experience
Although BioFutureRx is a new company, our team and affiliated network bring decades of experience in-licensing pharmaceutical products into the U.S. and Canadian markets — including the sourcing, diligence, deal structuring, and regulatory work that cross-border launches require.
Backed by a connected group
We work alongside sister companies spanning pharmaceutical in-licensing for the U.S. and Canadian market and investment and financing — so partners gain not just a commercialization route, but the relationships and capital behind it.
Explore our networkHow It Works
A clear path from evaluation to launch
- 01
Evaluate
We review your asset, its data package, and its regulatory status, then map the realistic U.S. opportunity and the gaps to close.
- 02
Structure
We agree the partnership model — license, distribution, or joint venture — and the commercial terms that fit your goals.
- 03
Register
We drive the FDA and regulatory pathway, coordinating CMC, supply, and the submissions that lead to approval.
- 04
Launch
We bring the product to market with the access, channel, and commercial support to establish it in the United States.
Who We Work With
Built for biologics companies looking to the U.S.
If you have a biologic and a U.S. ambition, we should talk. We are built to partner with developers and manufacturers based outside the United States.
- Ex-U.S. biosimilar developers seeking a U.S. commercial route
- Antibody and novel-biologic companies without a U.S. footprint
- Manufacturers with approved or late-stage biologics abroad
- Companies seeking a partner to share U.S. regulatory and launch risk